SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
MINNEAPOLIS, May 31, 2017 -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq:TCMD), a leader in developing and marketing at-home therapy devices for the treatment of lymphedema and chronic venous insufficiency, today announced that management will participate in the William Blair Growth Stock Conference at the Four Seasons Hotel in Chicago, Illinois. Management will host a presentation with investors on Tuesday, June 13, at 12:10 pm Central Time.
A live audio webcast of the presentation will be accessible under the “Events & Webcasts” section of the Company's investor relations website at http://investors.tactilemedical.com. An archive of the webcast will be available for replay following the conference.
About Tactile Medical
Tactile Medical is a leader in developing and marketing at-home therapy devices for the treatment of lymphedema and chronic venous insufficiency. Our unique offering includes advanced, clinically proven pneumatic compression devices, as well as continuity of care services provided by a national network of product specialists and trainers, reimbursement experts, patient advocates and clinicians. This combination of products and services ensures that tens of thousands of patients annually receive the at-home treatment necessary to better manage their chronic conditions. Tactile Medical takes pride in the fact that our solutions help increase clinical efficacy, reduce overall healthcare costs and improve the quality of life for patients with chronic conditions.
Investor Inquiries: Mike Piccinino, CFA Managing Director Westwicke Partners 443-213-0500 [email protected]
